Stock of the Day

Allarity Therapeutics (ALLR)

$0.90

-$0.00 (-0.3%)

Market Cap: $3.99M

About Allarity Therapeutics

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology.

Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Recent News

• ALLR Investors Have Opportunity to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm (prnewswire.com)
• Allarity Therapeutics, Inc.: Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission (finanznachrichten.de)
• Allarity sees cash runway into 2026 (markets.businessinsider.com)
• Allarity announces final settlement with SEC including $2.5M civil penalty (markets.businessinsider.com)
• Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission (globenewswire.com)